Inclusion Criteria:

- men aged 50 years or older

- diagnosed with adenocarcinoma prostate cancer

- will initiate and receive continuous ADT (luteinizing hormone releasing hormone
agonist (LHRH) or combination of LHRH and anti-androgen) for at least 12 months after
recruitment

- Patients will also consent to participating in the study.

Exclusion Criteria:

- severe cardiac disease (New York Heart Association class III or greater)

- angina

- severe osteoporosis

- uncontrolled hypertension (blood pressure > 160/95mm Hg)

- orthostatic blood pressure drop > 20mm Hg

- moderate to severe aortic stenosis

- acute illness or fever

- uncontrolled atrial or ventricular dysrhythmias

- uncontrolled sinus tachycardia (> 120 beats per minute)

- uncontrolled congestive heart failure third-degree atrio-ventricular heart block,
active pericarditis or myocarditis, recent embolism, thrombophlebitis, deep vein
thrombosis, resting ST displacement (> 3mm), uncontrolled diabetes, uncontrolled
pain, cognitive impairment, history of falls due to balance impairment or lost of
consciousness, severe neuromusculoskeletal conditions that limit their ability to
perform walking exercise (including ataxia, peripheral or sensory neuropathy,
unstable bone lesion, severe arthritis, pathological lower limb fractures within 6
months, lower limb amputation).